BioCentury
ARTICLE | Clinical News

Cylexin CY-1503: Began a Phase II trial

August 8, 1994 7:00 AM UTC

Cytel Corp. (CYTL), San Diego Product: Cylexin CY-1503 carbohydrate blocker of the cell adhesion molecule selectin Indication: Reduce reperfusion injury after surgery (pulmonary thromboendarterectomy)...